A double‐blind study on clonazepam in patients with burning mouth syndrome

Heckmann, Siegfried M.; Kirchner, Elena; Grushka, Miriam; Wichmann, Manfred; Hummel, Thomas

doi:10.1002/lary.22490

Cited by 123 publications

(161 citation statements)

References 21 publications

Supporting

Mentioning

152

Contrasting

Unclassified

Order By: Relevance

“…A recent placebo-controlled study in 20 BMS patients reported a significant reduction in pain following 0.5 mg of oral clonazepam daily for 9 weeks in this study 28. However, concerns about systemic absorption of topical or systemic therapy, potential dependence especially for systemic clonazepam, and a lack of long-term data limit its potential value in the therapy of BMS.…”

Section: Managementmentioning

confidence: 64%

Managing a patient with burning mouth syndrome

Cheung

Trudgill

2014

Frontline Gastroenterol

View full text Add to dashboard Cite

A 64-year-old woman presented with an increasing frequency of symptoms of heartburn and retrosternal pain over the last few months, and a constant and intense burning pain affecting her tongue tip, mouth and lips for the past 5 years. She found consuming hot drinks exacerbated the burning oral pain and chewing gum seemed to alleviate some of her symptoms. She thought these oral sensations were caused by frequently licking her finger tips to separate prints in her work in publishing. She had been previously diagnosed with gastro-oesophageal reflux disease (GORD), and her heartburn symptoms had been controlled until recently with lansoprazole 15 mg daily. Her past medical history included irritable bowel syndrome and depression, for which she had been treated with mebeverine and paroxetine for a number of years. She was a non-smoker and did not consume alcohol. Clinical examination was unremarkable with no oral lesions on examination. Her routine laboratory tests, including autoimmune serology, haematinics and thyroid function tests were all within normal limits. She underwent a gastroscopy, which revealed moderate reflux oesophagitis, and following commencing omeprazole 20 mg twice daily, her heartburn resolved. However, her oral burning symptoms were not affected and a diagnosis of burning mouth syndrome (BMS) was made. Following explanation and reassurance concerning the cause of her BMS symptoms, she chose not to receive treatment for this but to access cognitive behavioural therapy in the future if her symptoms worsened.

show abstract

Section: Managementmentioning

confidence: 64%

Managing a patient with burning mouth syndrome

Cheung

Trudgill

2014

Frontline Gastroenterol

View full text Add to dashboard Cite

show abstract

“…209 Clonazepam may affect taste sensation. 236,237 Topical clonazepam has been used in the management of neuropathic oral conditions and anecdotal data in taste and smell complaints have been published. 238,239 Topical application, while relatively benign, may be a problem for patients with little or no saliva.…”

Section: Managementmentioning

confidence: 99%

Oral complications of cancer and cancer therapy

Epstein

Thariat

Bensadoun

et al. 2012

CA A Cancer J Clinicians

411

356

View full text Add to dashboard Cite

Answer questions and earn CME/CNEOral complications resulting from cancer and cancer therapies cause acute and late toxicities that may be underreported, underrecognized, and undertreated. Recent advances in cancer treatment have led to changes in the incidence, nature, and severity of oral complications. As the number of survivors increases, it is becoming increasingly recognized that the aggressive management of oral toxicities is needed to ensure optimal long‐term oral health and general well‐being. Advances in care have had an impact on previously recognized oral complications and are leading to newly recognized adverse effects. Here, the authors briefly review advances in cancer therapy, including recent advances in surgery, oral care, radiation therapy, hematopoietic cell transplantation, and medical oncology; describe how these advances affect oral health; and discuss the frequent and/or severe oral health complications associated with cancer and cancer treatment and their effect upon long‐term health. Although some of the acute oral toxicities of cancer therapies may be reduced, they remain essentially unavoidable. The significant impact of long‐term complications requires increased awareness and recognition to promote prevention and appropriate intervention. It is therefore important for the primary oncologist to be aware of these complications so that appropriate measures can be implemented in a timely manner. Prevention and management is best provided via multidisciplinary health care teams, which must be integrated and communicate effectively in order to provide the best patient care in a coordinated manner at the appropriate time. CA Cancer J Clin 2012. © 2012 American Cancer Society.

show abstract

“…7 As clonazepam has strong effects on the brain serotonergic system, it also promotes descending pain inhibition, and suppresses the spontaneous central neuronal hyperactivity due to deafferentation. 50 Although the functions of the GABA-A receptor in the peripheral tissues are poorly understood, one may assume that a change in receptor density or ligand concentration may be related to the burning pain stomatodynia. This change may be triggered by neurosteroid deprivation.…”

Section: Clonazepammentioning

confidence: 99%

Burning Mouth Syndrome

Ducasse

Courtet

Olié

2013

Regional Anesthesia and Pain Medicine

View full text Add to dashboard Cite

Primary burning mouth syndrome (BMS) is defined as an "intraoral burning for which no medical or dental cause was found." Lifetime prevalence ranges from 3.7% to 18% - 40% in the elderly. There is no consensus among experts on the diagnostic criteria of BMS, the etiology is poorly understood, and there are no existing clinical guidelines. Therefore, BMS is often underdiagnosed and its management complex. For patients with BMS, this lack of clinical expertise may result in decreased quality of life and increased psychological distress.We conducted a systematic review to identify clinical features, pathophysiology, and therapeutic strategies for BMS. We discuss the multifactorial origin, involving peripheral nerve dysfunction and hormonal dysfunction, as well as psychological traits. We also describe the results of randomized clinical trials for each treatment through a pathophysiologic approach. This review should help clinicians recognize BMS, understand its pathophysiology, and gain an enhanced scientific understanding of therapeutic alternatives.

show abstract

A double‐blind study on clonazepam in patients with burning mouth syndrome

Abstract: Clonazepam appears to have a positive effect on pain in BMS patients.

Cited by 123 publications

References 21 publications

Managing a patient with burning mouth syndrome

Managing a patient with burning mouth syndrome

Oral complications of cancer and cancer therapy

Burning Mouth Syndrome

Contact Info

Product

Resources

About